STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3361 by analyst upside · 2026-08-12
ABT
Abbott Laboratories
Healthcare · Market Cap $190B · P/E 35.6x
ANALYST PRICE TARGET
+7.9%
implied upside to consensus target
Current Price $109.72
Consensus Target $118.42
Bull Target $135.0
Bear Target $103.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
14
Hold
6
Sell
0
52-Week Low $81.97
52-Week High $137.49
YTD Return -10.0%
FUNDAMENTALS
Market Cap $190B
P/E Ratio (TTM) 35.6x
Forward P/E 18.1x
EPS (TTM) $3.08
PEG Ratio 2.19
Dividend Yield 2.32%
Revenue (TTM) $46.6B
Profit Margin 11.6%
52-WEEK RANGE
52-Week Low $81.97
52-Week High $137.49
Current Price $109.72
Bear Target $103.0
Bull Target $135.0
● Now $109.72 ● Target $118.42
TRADING DATA
Avg Volume 12.5M
YTD Return -10.0%
Analyst Count 24
Consensus Buy
Upside to Target +7.9%
Last Updated 2026-08-12

ANALYST SUMMARY

Abbott Laboratories (ABT) is currently trading at $109.72 with a Wall Street consensus price target of $118.42, implying potential upside of 7.9% over the next 12 months. 24 analysts currently cover ABT, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $135.0, while the most cautious has a target of $103.0.

ABT operates in the Healthcare sector with a market capitalisation of $190B. The stock is down 10.0% year-to-date and is currently trading near the lower end of its 52-week range of $81.97 – $137.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ABT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-04-27 38% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-04-20 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-04-17 14% win rate (7 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-04-17 14% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-04-17 Building track record
Benchmark - Reiterated
Buy → Buy 2026-04-17 Building track record
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-04-17 Building track record
B of A Securities - Reiterated
Buy → Buy 2026-04-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
63
out of 100
Coverage depth
25/30
Consensus clarity
24/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →